uploads///Fast acting

Novo Nordisk’s Fast-Acting Insulins: A Performance Overview

By

Aug. 14 2018, Updated 7:31 a.m. ET

Fast-acting insulin segment revenue trends

In the first half of 2018, Novo Nordisk’s fast-acting insulins segment generated revenues of 9.7 billion Danish kroner, reflecting a ~2% YoY (year-over-year) growth in local currencies.

In the same period in the United States, Europe, AAMEO (Asia, Africa, the Middle East, and Oceania), and China, Novo Nordisk’s fast-acting insulins saw a ~5% decline, a ~7% growth, a ~19% growth, and a ~17% growth, respectively, YoY in local currencies.

Novo Nordisk’s (NVO) fast-acting insulins generated revenues of 4.9 billion Danish kroner in the second quarter of 2018, reflecting a ~4% YoY growth in local currencies.

Article continues below advertisement

In the second quarter of 2018 in the United States, Europe, AAMEO, and China, its fast-acting insulins generated revenues of 2.4 billion Danish kroner, 1.15 billion Danish kroner, 631 million Danish kroner, and 360 million Danish kroner, respectively. That’s a ~3% decline, a ~7% growth, a ~23% growth, and a ~17% growth, respectively, YoY in local currencies.

In the same quarter in Japan and Korea and Latin America, Novo Nordisk’s fast-acting insulins reported revenues of 198 million Danish kroner and 84 million Danish kroner, respectively. That’s a ~14% decline and a ~34% growth, respectively, YoY in local currencies.

In Europe, China, Japan and Korea, and Latin America, its fast-acting insulin revenues were primarily from sales of NovoRapid.

NovoRapid revenue trends

Novo Nordisk’s NovoRapid generated revenues of 9.5 billion Danish kroner in the first half of 2018. The drug’s revenues were flat in local currencies compared to 2017.

In the first half of 2018 in the United States, Europe, AAMEO, and China, NovoRapid generated revenues of 4.8 billion Danish kroner, 2.1 billion Danish kroner, 1.1 billion Danish kroner, and 729 million Danish kroner, respectively. In the same period in the United States, AAMEO, and China, Novo Rapid fell ~6%, grew ~19%, and grew 17%, respectively, YoY in local currencies.

NovoRapid reported revenues of 4.8 billion Danish kroner in the second quarter of 2018, reflecting a ~1% growth in local currencies. In Q2 2018 in the United States and Europe, it generated revenues of 2.4 billion Danish kroner and 1.1 billion Danish kroner, respectively. In the US market in Q2 2018, the drug saw a ~5% YoY decline in local currencies. In Europe, its revenues were flat compared to Q2 2017.

Eli Lilly’s (LLY) Humalog and Sanofi’s (SNY) Apidra, both NovoRapid’s competitors in the fast-acting insulins market, generated revenues of $769.8 million and 129 million euros, respectively, in the second quarter of 2018.

Advertisement

More From Market Realist

  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.